BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 30987843)

  • 21. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy.
    Knipper S; Ascalone L; Ziegler B; Hohenhorst JL; Simon R; Berliner C; van Leeuwen FWB; van der Poel H; Giesel F; Graefen M; Eiber M; Heck MM; Horn T; Maurer T
    Eur Urol; 2021 Apr; 79(4):537-544. PubMed ID: 33317857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery.
    Mehring G; Steinbach C; Pose R; Knipper S; Koehler D; Werner S; Riethdorf S; von Amsberg G; Ambrosini F; Maurer T
    World J Urol; 2024 Apr; 42(1):256. PubMed ID: 38656636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [PSMA-radioguided surgery in localized recurrent prostate cancer : Current and future aspects].
    Rauscher I; Eiber M; Jilg CA; Gschwend JE; Maurer T
    Urologe A; 2017 Jan; 56(1):18-23. PubMed ID: 27885455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel technology of molecular radio-guidance for lymph node dissection in recurrent prostate cancer by PSMA-ligands.
    Rauscher I; Horn T; Eiber M; Gschwend JE; Maurer T
    World J Urol; 2018 Apr; 36(4):603-608. PubMed ID: 29372353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
    Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
    Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
    Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Mena E; Lindenberg ML; Turkbey IB; Shih JH; Harmon SA; Lim I; Lin F; Adler S; Eclarinal P; McKinney YL; Citrin D; Dahut W; Wood BJ; Krishnasamy V; Chang R; Levy E; Merino M; Pinto P; Eary JF; Choyke PL
    J Nucl Med; 2020 Jun; 61(6):881-889. PubMed ID: 31676732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of
    Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T
    BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment Outcomes from
    Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [No Abstract]   [Full Text] [Related]  

  • 31. Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.
    Bianchi L; Castellucci P; Farolfi A; Droghetti M; Artigas C; Leite J; Corona P; Shagera QA; Moreira R; González C; Queiroz M; de Galiza Barbosa F; Schiavina R; Deandreis D; Fanti S; Ceci F
    Eur Urol Oncol; 2023 Feb; 6(1):41-48. PubMed ID: 34933814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of relapse as determined by
    Henkenberens C; Derlin T; Bengel FM; Ross TL; Wester HJ; Hueper K; Kuczyk MA; Christiansen H; von Klot CA
    Strahlenther Onkol; 2018 Apr; 194(4):303-310. PubMed ID: 29134231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study.
    Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Langkilde NC; Jensen JB; Petersen LJ
    Clin Nucl Med; 2018 Aug; 43(8):579-585. PubMed ID: 29916917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series.
    Francolini G; Detti B; Bottero M; Zilli T; Lancia A; Bruni A; Borghesi S; Mariotti M; Castellucci P; Fanti S; Filippi AR; Teriaca MA; Maragna V; Aristei C; Mazzeo E; Livi L; Ingrosso G
    Clin Transl Oncol; 2021 Feb; 23(2):364-371. PubMed ID: 32602076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis.
    Subiela JD; Gomis Sellés E; Maldonado A; Lopez Campos F; Aumatell Ovide J; Ajuria Illarramendi O; González-Padilla DA; Gajate P; Ortega Polledo LE; Alonso Y Gregorio S; Guerrero-Ramos F; Gómez Dos Santos V; Rodríguez-Patrón R; Calais J; Kishan AU; Burgos Revilla FJ; Couñago F
    Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e676-e688. PubMed ID: 37802722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
    Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
    Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
    Gandaglia G; Mazzone E; Stabile A; Pellegrino A; Cucchiara V; Barletta F; Scuderi S; Robesti D; Leni R; Samanes Gajate AM; Picchio M; Gianolli L; Brembilla G; De Cobelli F; van Oosterom MN; van Leeuwen FWB; Montorsi F; Briganti A
    Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
    Ferraro DA; Rüschoff JH; Muehlematter UJ; Kranzbühler B; Müller J; Messerli M; Husmann L; Hermanns T; Eberli D; Rupp NJ; Burger IA
    Theranostics; 2020; 10(14):6082-6094. PubMed ID: 32483440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer.
    Maurer T; Schwamborn K; Schottelius M; Wester HJ; Schwaiger M; Gschwend JE; Eiber M
    Clin Genitourin Cancer; 2016 Oct; 14(5):e549-e552. PubMed ID: 27318956
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.